51. Polymersomes conjugated to 83-14 monoclonal antibodies: in vitro targeting of brain capillary endothelial cells
- Author
-
Dalin Wu, Le-Ha Dieu, Cornelia G. Palivan, Jörg Huwyler, and Vimalkumar Balasubramanian
- Subjects
medicine.drug_class ,Polymers ,Drug delivery to the brain ,Pharmaceutical Science ,In Vitro Techniques ,Blood–brain barrier ,Monoclonal antibody ,Microscopy, Electron, Transmission ,medicine ,Humans ,Receptor ,Cell Line, Transformed ,Microscopy, Confocal ,biology ,Chemistry ,Vesicle ,Antibodies, Monoclonal ,Brain ,Endothelial Cells ,General Medicine ,Flow Cytometry ,Molecular biology ,Endocytosis ,Insulin receptor ,medicine.anatomical_structure ,Polymersome ,Biophysics ,biology.protein ,Nanocarriers ,Biotechnology ,Subcellular Fractions - Abstract
The blood-brain barrier (BBB) remains an obstacle for many drugs to reach the brain. A strategy to cross the BBB is to modify nanocarrier systems with ligands that bind to endogenous receptors expressed at the BBB to induce receptor-mediated transport. The aim of the present study was to investigate the potential of polymersomes composed of the amphiphilic diblock copolymer poly(dimethylsiloxane)-block-poly(2-methyl-2-oxazoline), PDMS-b-PMOXA, for active targeting of brain capillary endothelial cells. We conjugated PDMS-b-PMOXA polymersomes to the anti-human insulin receptor antibody 83-14 and studied their uptake by brain capillary endothelial cells. Transmission electron micrography and light scattering measurements revealed the self-assembly of the block copolymers into 200 nm vesicles after extrusion. Fluorescence correlation spectroscopy was employed to calculate the number of antibodies coupled to one polymersome. Binding and uptake of the polymersomes conjugated to 83-14 mAb were studied in the human BBB in vitro model hCMEC/D3 expressing the human insulin receptor. Competitive inhibition with an excess of free 83-14 mAb demonstrated the specificity of cellular binding and uptake. Our results suggest that PDMS-b-PMOXA polymersomes conjugated to 83-14 mAb may be suitable nanocarriers for drug delivery to the brain.
- Published
- 2014